Circulating microRNA-1 as a diagnostic biomarker for acute myocardial infarction: a meta-analysis

The aim of this study was to evaluate the diagnostic performance of microRNA-1 in the diagnosis of acute myocardial infarction (AMI).

PubMed, Embase, Cochrane, Web of science and CNKI databases were searched by computer to collect English literature evaluating the diagnostic value of microRNA-1 in AMI patients. The retrieval period is from the establishment of the database to September 2023. Two researchers independently screened the literature according to inclusion and exclusion criteria, extracted data, and evaluated the risk of bias in the included studies using QUADAS-2 tools. Stata15.0 software was used for meta-analysis. The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the summary receiver operator characteristic (SROC) curve were calculated.

This study included 11 pieces of literature, which included 894 patients with AMI and600 controls. The main results of meta-analysis were as follows: The pooled sensitivity and specificityof microRNA-1 for the diagnosis of AMI were 78% (95% CI: 0.69-0.85) and 85% (95% CI: 0.76-0.91), respectively, the positive likelihood ratio was 5.1 (95%CI: 3.0-8.6), the negative likelihood ratio was 0.26 (95% CI: 0.17-0.38), the diagnostic odds ratio was 20 (95% CI: 9-47), and the area under the SROC curve (AUC) was 88% (95% CI: 0.85-0.91).

Plasma microRNA-1 has high sensitivity and specificity for early AMI, and has certain diagnostic value, which can help distinguish AMI from patients with other systemic diseases, and can be combined with other biomarkers to diagnose AMI.